GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
-7.63%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$388M
AUM Growth
+$388M
(-6.1%)
Cap. Flow
+$5.08M
Cap. Flow
% of AUM
1.31%
Top 10 Holdings %
Top 10 Hldgs %
56.11%
Holding
41
New
11
Increased
11
Reduced
7
Closed
7
Top Buys
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$18.9M |
| 2 |
Sarepta Therapeutics
SRPT
|
$14.5M |
| 3 |
Nektar Therapeutics
NKTR
|
$12M |
| 4 |
CINC
CinCor Pharma, Inc. Common Stock
CINC
|
$11.1M |
| 5 |
Alkermes
ALKS
|
$10.8M |
Top Sells
| 1 |
Exelixis
EXEL
|
$29.5M |
| 2 |
BCYC
Bicycle Therapeutics
BCYC
|
$24.2M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$22.2M |
| 4 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
$19M |
| 5 |
Rigel Pharmaceuticals
RIGL
|
$12M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Xenon Pharmaceuticals
XENE
$2.98B
| $33.6M | 8.06% | 1,104,334 +184,334 | +20% | +$5.61M |
|
2
Jazz Pharmaceuticals
JAZZ
$7.75B
| $29.6M | 7.11% | 190,000 +35,000 | +23% | +$5.46M |
|
3
Cytokinetics
CYTK
$4.23B
| $24M | 5.75% | 610,000 -40,000 | -6% | -$1.57M |
|
4
Travere Therapeutics
TVTX
$1.56B
| $23.5M | 5.64% | 971,233 -38,767 | -4% | -$939K |
|
5
Vaxcyte
PCVX
$4B
| $21.4M | 5.14% | 985,153 +100,000 | +11% | +$2.18M |
|
6
Galapagos
GLPG
$2.07B
| $20.1M | 4.82% | 360,000 | – | – |
|
|
KRTX
7
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $18.9M | 4.52% | +149,000 | New | +$18.9M |
|
|
PNT
8
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $16.5M | 3.95% | 2,420,501 +360,501 | +18% | +$2.46M |
|
9
Aclaris Therapeutics
ACRS
$209M
| $15.1M | 3.63% | 1,083,000 +140,555 | +15% | +$1.96M |
|
10
KalVista Pharmaceuticals
KALV
$678M
| $15.1M | 3.61% | 1,530,000 +655,803 | +75% | +$6.45M |
|
|
11
Sarepta Therapeutics
SRPT
$1.78B
| $14.5M | 3.49% | +193,900 | New | +$14.5M |
|
12
Relmada Therapeutics
RLMD
$37.2M
| $13.3M | 3.19% | 700,000 -90,000 | -11% | -$1.71M |
|
|
CINC
13
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| $12.6M | 3.02% | 669,200 +589,530 | +740% | +$11.1M |
|
|
14
Nektar Therapeutics
NKTR
$568M
| $12M | 2.87% | +3,150,000 | New | +$12M |
|
15
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $11.7M | 2.8% | 1,204,028 +85,961 | +8% | +$833K |
|
|
TCDA
16
DELISTED
Tricida, Inc. Common Stock
TCDA
| $11.3M | 2.7% | 1,164,763 -85,237 | -7% | -$825K |
|
|
17
Alkermes
ALKS
$4.78B
| $10.8M | 2.58% | +361,636 | New | +$10.8M |
|
18
Precision BioSciences
DTIL
$57.8M
| $9.21M | 2.21% | +5,755,396 | New | +$9.21M |
|
19
AnaptysBio
ANAB
$569M
| $9.2M | 2.21% | 453,118 -246,882 | -35% | -$5.01M |
|
20
Neurocrine Biosciences
NBIX
$13.8B
| $7.31M | 1.75% | +75,000 | New | +$7.31M |
|
21
Avidity Biosciences
RNA
$5.99B
| $7.27M | 1.74% | 500,000 | – | – |
|
22
UroGen Pharma
URGN
$900M
| $7.15M | 1.72% | 873,424 | – | – |
|
23
Acumen Pharmaceuticals
ABOS
$82.4M
| $7.12M | 1.71% | 1,515,000 +586,718 | +63% | +$2.76M |
|
|
KDNY
24
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $5.89M | 1.41% | 336,731 -1,086,951 | -76% | -$19M |
|
25
Ventyx Biosciences
VTYX
$171M
| $4.76M | 1.14% | 389,223 +52,889 | +16% | +$647K |
|